Abstract: The United States is the largest drug market, 40 out of the 53 new molecule entities (NME) or biologics license applications (BLA) approved by the Food and Drug Administration (FDA) were first approvals over the world. In addition, Europe and Japan are also the major markets for global innovative drugs. In the products approved by the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), 6 and 13 were firstly approved globally, respectively. The marketing of these new drugs will solve the problem with many diseases lacking effective treatments, and provide new therapeutic options for some indications. Hereby we briefly introduce and review the R&D history, clinical effects and marketing prospective of the new drugs firstly approved by FDA, EMA and PMDA in 2020, so as to provide reference for new drug researchers.